Cibisatamab is a T-cell bispecific antibody (TCB) that uses a 2-to-1 molecular format to target carcinoembryonic antigen (CEA) expressed on the surface of tumour cells and CD3ε on T cells9. Here, CEACAM5 is linked to neoplasm.